Dr. Ma Liguo is currently the Director of Technology Research and Development at Nantong Qiangsheng Graphene Technology Co., Ltd., and a member of the Standardization Technical Committee of the China Chemical Fibers Association. He has published more than 10 SCI papers in internationally renowned journals such as *Angewandte Chemie International Edition*, and holds 3 related technology patents (including authorized invention patents). He has long been engaged in the development and application of graphene composite functional fibers, responsible for introducing graphene materials into textile fiber systems, developing modified fibers and fiber products with functions such as antibacterial, far-infrared, and antistatic properties. He also emphasizes the connection between product development and production processes, improving product consistency and safety by supervising the formulation of operating standards and continuously optimizing production processes and formulations, enabling the company's related products to enjoy a good reputation in European and American markets over the long term. He has successively received titles such as "Innovation Leading Talent" and "Fuhai Talent" of Rudong County, Jiangsu Province. He led the enterprise to win the first "Golden Phoenix Tree" Award of Rudong County, and was rated as an outstanding county-external employee of Rudong enterprises in the second session. His technical accumulation in graphene-modified fibers and subsequently in graphene 3D printing filaments is a typical practice of graphene moving from powder to textile and additive manufacturing end products. At the conference's Future Health Forum, he plans to share his experience in the research, development, and industrialization of graphene functional fibers.
Important Honors: Member of the Standardization Technical Committee of the China Chemical Fibers Association; "Innovation Leading Talent" and "Fuhai Talent" of Rudong County, Jiangsu Province; Outstanding County-External Employee of Rudong Enterprises in the second session.
